gefitinib has been researched along with Carcinoma, Papillary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S | 1 |
| Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H | 1 |
| Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G | 1 |
| Espina, V; Godwin, AK; Hussain, MM; Kohn, EC; Kwitkowski, V; Liel, MS; Minasian, L; Posadas, EM; Steinberg, SM; Wood, BJ | 1 |
| Clark, JR; Daniels, GH; Evans, T; Fidias, PH; Gurubhagavatula, S; Haddad, RI; Heist, RS; Lynch, TJ; Pennell, NA; Ross, DS; Temel, JS; Wirth, LJ | 1 |
2 trial(s) available for gefitinib and Carcinoma, Papillary
| Article | Year |
|---|---|
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Treatment Outcome | 2007 |
A phase II study of gefitinib in patients with advanced thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Papillary; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Quinazolines; Severity of Illness Index; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2008 |
3 other study(ies) available for gefitinib and Carcinoma, Papillary
| Article | Year |
|---|---|
A case report of thyroid cancer showing a remarkable effect of gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2011 |
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |